| Tumour group / site | Trial title | Date opened
|
|---|
BREAST
| A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer BCCA CODE: BRT756
| 4 Oct 2019
|
| A phase II trial of abbreviated hormone therapy for low risk hormone receptor positive, HER2 negative early breast cancer BCCA CODE: BRLALEAST | 23 Sep 2019
|
| A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE). BCCA CODE: BRTNATALEE | 19 Jun 2019
|
| A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH NEOADJUVANT DOXORUBICIN + CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL + TRASTUZUMAB + PERTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER BCCA CODE: BRT40747 | 27 May 2019
|
| A Phase 1/2 study for the
safety, efficacy, pharmacokinetic and pharmacodynamics evaluation of SAR439859,
administered orally as monotherapy, then in combination with palbociclib in
postmenopausal women with estrogen receptor-positive advanced breast cancer BCCA CODE: BRTSERD (on hold as of 1May2019)
| 1 May 2019
|
| A PHASE Ib AND OPEN LABEL PHASE II STUDY OF CFI-402257 IN COMBINATION WITH WEEKLY PACLITAXEL IN PATIENTS WITH ADVANCED/METASTATIC HER2-NEGATIVE BREAST CANCER
BCCA CODE: BRIND236
| 16 Apr 2019
|
| CARA Pilot STUDY: A Novel Breast Positioning Device to Reduce Toxicity in Radiotherapy for Breast Cancer
BCCA CODE: CARA
| Sept 2018
|
| Prospective Outcomes and Support Initiative: Breast Skin Pilot (B-SkiP)
BCCA CODE: POSI B-SkiP
| Aug 2018
|
| A phase IIIb, single-arm, open-label multicentre study of olaparib monotherapy in the treatment of HER2-ve metastatic breast cancer patients with germline BRCA1/2 mutations
BCCA CODE: BRTLUCY
| 18 May 2018
|
| A Randomized Phase III Double Blinded Placebo Controlled Trial Of Aspirin As Adjuvant Therapy For HER2 Negative Breast Cancer: The ABC Trial
BCCA CODE: BRMAC21
| 9 May 2018
|
| A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, TRIPLE-NEGATIVE BREAST CANCER OR HORMONE RECEPTOR–POSITIVE, HER2-NEGATIVE BREAST CANCER
BCCA CODE: BRTIPATUNI
| 01 May 2018
|
| A phase II, multicenter, open-label, two-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, horone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment
BCCA CODE: BRTBYLIEVE
| March 2018
|
| A study evaluating the pregnancy outcomes and safety of interupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (positive)
BCCA CODE: BRMAC18
| July 2017
|
| Treatment of Canadian Postmenopausal Women with ER+ Advanced Breast Cancer in the Real-World Setting with Hormone Therapy
BCCA CODE: BRTYCA09 | November 2016 |
CENTRAL NERVOUS
SYSTEM (CNS) | Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma (N0577) BCCA CODE: CNCE6RT | 4 Nov 2019
|
| A PHASE III TRIAL OF MARIZOMIB IN COMBINATION WITH STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY VERSUS STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
BCCA CODE: CNCE8RT
| 26 Mar 2019
|
GASTROINTESTINAL (GI)
| A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Gastric Cancer (FRACTION-Gastric Cancer) BCCA CODE: GITFRACTIO | 22 Jul 2019
(currently on hold)
|
| An open-label, multi-center, Phase 1b study to investigate the safety and tolerability of SLC-0111 (WBI-5111)1 in combination with gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma subjects positive for Carbonic Anhydrase IX
BCCA CODE: GITSLCGEM
| 10 Jan 2019
|
| Neoadjuvant chemotherapy, Excision and Observation for early rectal cancer (CCTG)
BCCA CODE: GICO28
| 21 Jun 2018
|
| A PHASE III, RANDOMISED, INTERNATIONAL TRIAL COMPARING mFOLFIRINOX TRIPLET CHEMOTHERAPY TO mFOLFOX FOR HIGH RISK STAGE III COLON CANCER IN ADJUVANT SETTING (IROCAS STUDY)
BCCA CODE: GICO27
| April 2018
|
| COMPHREHENSIVE GENOMIC PROFILING OF COLORECTAL CANCER PATIENTS WITH ISOLATED LIVER METASTASES TO UNDERSTAND RESPONSE & RESISTANCE TO CANCER THERPAY
BCCA CODE: GICOMPARIS
| April 2018
|
| Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma subtypes by comprehensive Genomic Analysis
BCCA CODE: GITPANGEN | February 2017
|
| A phase lll study of the impact of a physical activity program on disease-free survival in patients with high risk stage ll or stage lll colon cancer: a randomized controlled trial (challenge) BCCA CODE: GICO21
| July 2009
|
GENITOURINARY (GU) - BLADDER
| A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer (NIAGARA)
BCCA CODE: GUTNIAGARA
| 30 Apr 2019
|
| A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer
BCCA CODE: GUTNILE
| 5 Feb 2019
|
| A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
BCCA CODE: GUTTHOR
| 4 Jan 2019
|
| An Open-label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
BCCA CODE: GUTEV301
| 13 Dec 2018
|
| A phase III, open-label, multicenter, randomized study of atezolizumab (anti-PD-L1 antibody) versus observation as adjuvant therapy in patients with PD-L1-selected, high risk muscle-invasive bladder cancer after cystectomy
BCCA CODE: GUT29636 | March 2016 |
GENITOURINARY (GU) - Kidney
|
A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse BCCA CODE: GUT914 |
22 Aug 2018
|
| A multi-center, open label, randomized phase II study of AGS-16C3F vs axitinib in metastatic renal cell carcinoma
BCCA CODE: GUT16C3F
| April 2016
|
| GENITOURINARY (GU) - Testis | Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma with Isolated Retroperitoneal Disease (1-3cm)
BCCA CODE: GUSEMS | 11 Sep 2018
|
| GENITOURINARY (GU) - Prostate
| A Phase 3, Randomized Open-label Study of
Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or
Enzalutamide in Participants with Metastatic Castration resistant
Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair
Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent
(NHA) and Chemotherapy (KEYLYNK-010)
BCCA CODE: GUTKL010
| 8 Oct 2019
|
| A Phase 1, First-in-Human, Dose Escalation Study of JNJ-63898081 in Subjects with Advanced Stage Solid Tumors
BCCA CODE: GUT1001
| 9 Jul 2019
|
| A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer
BCCA CODE: GUTNIRA001
| 2 May 2019
|
| VISION: AN INTERNATIONAL, PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF 177LU-PSMA-617 IN THE TREATMENT OF PATIENTS WITH PROGRESSIVE PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
BCCA CODE: GUTVISION
| 17 Jan 2019
|
| A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
BCCA CODE: GUTQUEST
| 30 Oct 2018
|
| A Phase II Study of Palbociclib, a CDK4/6 Inhibitor, In Patients With Metastatic Castration-Resistant Prostate
BCCA CODE: GUIND223
| 22 Aug 2018
|
| Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study
BCCA CODE: GUIND234
| 22 Aug 2018
|
| A Multicentre Cohort Study of Patients with Advanced Prostate Cancer in Canada
BCCA CODE: GURC
| 3 Jul 2018
|
| An International Registry for Men with Advanced Prostate Cancer
BCCA CODE: IRONMAN
| April 2018
|
| A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
BCCA CODE: GUTCR2001
| December 2017
|
| A phase I/II open-label study to assess the safety, pharmcokinetics, and anti-tumor activity of oral EPI-506 in patients with metastatic castration-resistant prostate cancer
BCCA CODE: GUTCS0001
(on HOLD as of January 9, 2015) | December 2015 |
GYNECOLOGY
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer BCCA CODE: GOT826
| 18 Oct 2019
|
| A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (3000-03-005/ENGOT-OV44)
BCCA CODE: GOTFIRST
| 4 Jun 2019
|
| An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator’s Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma
BCCA CODE: GOTEMPOWER
| 04 Oct 2018
|
| Phase I (Safety Assessment) of Durvalumab (MEDI4736) with Focal Sensitizing Radiotherapy in Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Epithelial Carcinoma
BCCA CODE: GOTABSRT (re-opened 24Jun2019)
| 28 May 2018
|
| A Retrospective/
Prospective Analysis of Characterization of the Long-Term Responders on Olaparib in Solid Tumours BCCA CODE:
GOTOZM061
| August 2017
|
| A phase 3 randomized, double-blind, placebo-controlled multicentre study of Niraparib maintenance treatment in patients with HRD-positive advanced ovarian cancer following response to front-line platinum-based chemotherapy
BCCA CODE: GOTPRIMA | February 2017 |
| HEAD & NECK |
|
|
LUNG
| A randomized,
double-blind, placebo-controlled, phase III study evaluating the efficacy and
safety of canakinumab in combination with docetaxel vs placebo in combination
with docetaxel in subjects with non-small cell lung cancer previously
BCCA CODE: LUTCANOPY2
| 28 Jun 2019
|
| Open Label, Multicenter, Phase II Study of Patients with Treatment Naïve Metastatic Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer with Brain Metastases Randomized to Stereotactic Radiosurgery (SRS) and Osimertinib or Osimertinib Alone
BCCA CODE: LUOSICNS
| 19 Mar 2019
|
| A PHASE II STUDY OF POZIOTINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER, LOCALLY ADVANCED OR METASTATIC, WITH EGFR OR HER2 EXON20 INSERTION MUTATION
BCCA CODE: LUTPOZ202
| 4 Dec 2018
|
LYMPHOMA
| A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator's Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation
BCCA CODE: LYTACE311
| 3 Jun 2019
|
| A Phase 1/Phase 2 Clinical Study to Evaluate the Safety Of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies
BCCA CODE: LYT4280003
| 21 May 2019
|
| A PHASE IB/II STUDY EVALUATING THE SAFETY, TOLERABILITY AND ANTI-TUMOR ACTIVITY OF POLATUZUMAB VEDOTIN (DCDS4501A) IN COMBINATION WITH RITUXIMAB (R) OR OBINUTUZUMAB (G) PLUS BENDAMUSTINE (B) IN RELAPSED OR REFRACTORY FOLLICULAR OR DIFFUSE LARGE B-CELL LYMPHOMA
BCCA CODE: LYT29365 (re-opened with Arm H)
| 2 Jan 2019
|
| A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Positive Peripheral T-cell Lymphoma
BCCA CODE: LYTCHEPBV
| 10 Sep 2018
|
| A Phase 3, Randomized, Double‑blind, Placebo‑controlled, Multicenter Study of BR alone Versus in Combination with Acalabrutinib (ACP‑196) in Subjects with Previously Untreated Mantle Cell Lymphoma. (ACE-LY-308 ECHO MCL study) BCCA CODE: LYTACE308 | 26 Sep 2017
|
| A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refractory Hematologic malignancies
BCCA CODE: LYTTT1621 | May 2017
|
| An open-label, multicenter, phase I trial evaluating the safety and pharmacokinetics of escalating doses of BTCT4465A in patients with relapsed or refractory B-cell non-hodgkin's lymphoma and chronic lymphocytic leukemia (CLL)
BCCA CODE: LYT29781
| February 2016 |
| A multi-staged randomized phase II study of novel combination therapy in the treatment of relapsed and refractory aggressive B-cell lymphoma
BCCA CODE: LYLY17
| September
2015 |
| A phase IB/II, open-label study evaluting the safety and pharmacokenetics of GDC-0199 (ABT-199) in combination with rituximab(R) or obinutuzumab(G) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with B-cell non-hodgkin's lymphoma (NHL) and DLBCL
BCCA CODE: LYT27878 | February 2015 |
PHASE 1
| Phase 1/2 Open-label Study of MK-8353 in Combination with Selumetinib (MK-5618) in Participants with Advanced/Metastatic Solid Tumors
BCCA CODE: P1MK8353 | 23 Jul 2019
|
| A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001) BCCA CODE: P1TLIBRETO
| 5 Jun 2019
|
| A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers
BCCA CODE: P1TIL8 (18Sept2019 Part 1 enrollment expanded)
| 13 Dec 2018
|
| AN OPEN-LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR, HER2, HER3) MUTATIONS OR EGFR GENE AMPLIFICATION BCCA CODE: P1TPUMA201 | 29 Oct 2018
|
| A Phase 1/2, Open Label, Multicenter Study of the Combination of NKTR-214, and Nivolumab, or the Combination of NKTR-214, Nivolumab and ipilimumab in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies
BCCA CODE: P1TPIVOT02
| June 2018
|
| A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
BCCA CODE: P1PJC021
| April 2018
|
| CANADIAN PROFILING AND TARGETED AGENT UTILIZATION TRIAL (CAPTUR) A PHASE II BASKET TRIAL
BCCA CODE: P1PM1
| March 2018
|
| A phase-Ib dose-finding study of the SMAC mimetic Debio 1143 when given in combination with the anti-PD-L1 antibody avelumab to patients with advanced solid malignancies and, in an expansion cohort, to patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC)
BCCA CODE: P1T1143
| March 2018
|
| A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
BCCA CODE: P1PJC021
| January 2018
|
| A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
BCCA CODE: P1TGARNET
| September 2017
|
| A Phase I trial of MLN0128 (Tak-228) in combination with osimertinib (AZD9291) in advanced EGFR mutation positive non-small cell lung cancer (NSCLC) after progression on a previous EGFR tyrosine kinase inhibitor. BCCA CODE: P1PJC020 | September 2017 |
| A Phase II Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors
BCCA CODE: P1PJC022
| August 2017
|
| An open-label, dose escalation, safety, and pharmacokinetic study of CFI-402257 administered orally to patients with advanced solid tumours
BCCA CODE: P1T402257 | May 2017 |
| A phase II study of durvalumab (MEDI4736) and tremelimumab in patients with advanced rare tumours
BCCA CODE: MOIND228 | April 2017 |
| A phase I/Ib, open-label, multi-center, repeat-dose, dose-selection study of CPI-444 as single agent and in combination with atezolizumab in patients with selected incurable cancers
BCCA CODE: P1TCPI444
| February 2017 |
| A phase I/II study of CX5461
BCCA CODE: P1IND231
| September 2016 |
| A phase I/IIa study of BMS-986205 in combination with nivolumab (BMS-986558, anti PD-1 Monoclonal Antibody) in advanced malignant tumors
BCCA CODE: P1T986205
| April 2016 |
| A phase I trial of MK-3475 Plus Ziv-Aflibercept in patients with advanced solid tumours
BCCA CODE: P1PJC016 | August 2015 |
| A phase I trial of single agent trametinib (GSK1120212) in advanced cancer patients with dysfunction
BCCA CODE: P1PJC015 | June 2014 |
| SARCOMA |
| |
SKIN - MELANOMA
| A phase III randomized, double-blind, placebo-controlled study comparing the combination of PDR001, daBRAFenib and trametinib versus placebo, daBRAFenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant melanoma
BCCA CODE: SMTCOMBII
| 15 May 2018
|
| A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP)
BCCA CODE: SMME13
| October 2016
|
SYMPTOM MANAGEMENT/
SUPPORTIVE CARE
| A randomized, double-blind, placebo controlled crossover trial of the use of Subcutaneous Lidocaine Infusion (SCLI) for chronic cancer-related pain
BCCA CODE: LIDOCAINE | January 2012 |
| Sennosides PEG study
A randomized, double-blind, double-dummy, 2 treament, 2 period, cross-over comparison of Sennosides and Polyethylene Glycol for constipation in outpatients with cancer
BCCA CODE: SCTPEGSEN | April 2010 |
MULTIPLE
SITES
| Utilization of genomic information to augment chemotherapy decision-making for people with incurable malignancies
BCCA CODE: no BCCA code available | July 2012
|
